Johnson & Johnson (JNJ)

$238.46 -2.85 (-1.18%)
Market Cap 581.22B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 22.34
Forward PE 20.91
Profit Margin 28.46%
Debt to Equity Ratio 0.48
Volume 7,354,500
Avg Vol 8,371,434
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 34%
Beta 0.34
Analysts Strong Sell
Price Target $243.76

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
parcha
parcha Apr. 11 at 1:31 AM
Cramer warns of ‘overconfident’ market after U.S.-Iran ceasefire $JNJ Tuesday brings earnings from Johnson & Johnson as well. Cramer loves this drugmaker because of its robust pipeline. This stock does have a habit of “getting hammered,” Cramer said, on the initial earnings results, then rallying once the conference call with management starts. “If it gets blasted, try to get some,” he added. In fact, the Charitable Trust started a position in Johnson & Johnson on Wednesday. https://www.cnbc.com/2026/04/10/cramer-warns-overconfident-market-after-us-iran-ceasefire.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 10 at 11:33 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile. We also covered these names. $COST $V $JNJ $JPM
0 · Reply
Skimman
Skimman Apr. 10 at 8:22 PM
$JNJ Grab some BEERS and do some reading .... have a GREAT WEEKEND.. LOL
0 · Reply
Skimman
Skimman Apr. 10 at 8:18 PM
$JNJ Earnings Tuesday.. Conference this Weekend with new Drugs in Washington Dc.. hope u did u research.. Conference starts today and ends Sunday.. hahahaha.. lets see who is laughing on Monday/ Tuesday.. lol
0 · Reply
Suite510
Suite510 Apr. 10 at 7:55 PM
$JNJ lol 😂 🥃🎁
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 10 at 6:33 PM
$JNJ $UNH defensive flows still active, but not panic-driven more like steady allocation into stable earnings
0 · Reply
trenddetector
trenddetector Apr. 10 at 5:30 PM
$JNJ There are now Care Pathways and Diagnostic Paths mapped out for Prostate, Breast, Colorectal, Lung, Pancreatic, Lymphoma, Leukemia, Melanoma, Bladder, Ovarian, Kidney, Thyroid, Brain Liver and Uterine/Endometrial Cancer with more coming. www.yourcancerpath.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 10 at 4:36 PM
🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-04-17 | Strike: $240.00 | Type: PUT Option Plan (premium): Entry: $4.68 Stop: $3.37 TP1: $6.08 TP2: $7.95 TP3: $11.22 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
NellyBush
NellyBush Apr. 10 at 12:43 PM
$JNJ $PTGX Bofa inaugural Doctor day KOL expects JNJ’s recently launched Icotyde (Ico; oral IL-23) to be the best oral option available in psoriasis and believes everyone on Otezla/Sotyktu (in theory) should get switched to Ico (all else equal), thus expects a fair amount of usage.
0 · Reply
Laurenoni
Laurenoni Apr. 10 at 11:30 AM
$JNJ above the open, strong demand
0 · Reply
Latest News on JNJ
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 10, 2026, 8:00 AM EDT - 16 hours ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 9, 2026, 7:57 AM EDT - 1 day ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 8, 2026, 10:41 AM EDT - 2 days ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Apr 7, 2026, 8:00 AM EDT - 3 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 11 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 28, 2026, 10:00 AM EDT - 13 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 4:46 PM EDT - 14 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 27, 2026, 6:31 AM EDT - 14 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 22 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 19, 2026, 9:35 AM EDT - 22 days ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 23 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 1:17 PM EDT - 23 days ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 23 days ago

US FDA approves J&J's oral psoriasis pill

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 18, 2026, 7:49 AM EDT - 23 days ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 16, 2026, 11:00 AM EDT - 25 days ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 13, 2026, 12:35 PM EDT - 4 weeks ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 12, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 3:55 PM EST - 5 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

US FDA approves JNJ's blood cancer drug

Mar 5, 2026, 2:21 PM EST - 5 weeks ago

US FDA approves JNJ's blood cancer drug

Johnson & Johnson launches website for direct-to-consumer sales

Mar 4, 2026, 6:07 PM EST - 5 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 3, 2026, 8:03 AM EST - 5 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Mar 2, 2026, 4:30 PM EST - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 26, 2026, 2:30 PM EST - 6 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 24, 2026, 4:03 PM EST - 6 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 11:35 AM EST - 6 weeks ago

Does JNJ Stock Still Offer Value?

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:43 AM EST - 6 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 23, 2026, 10:28 AM EST - 6 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 21, 2026, 8:00 AM EST - 6 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 5:00 PM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:34 PM EST - 7 weeks ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 2:11 PM EST - 7 weeks ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:44 AM EST - 7 weeks ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:17 AM EST - 7 weeks ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 10:15 AM EST - 7 weeks ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 18, 2026, 7:30 AM EST - 7 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 8:00 AM EST - 7 weeks ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:19 PM EST - 2 months ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 4:18 PM EST - 2 months ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 2:43 PM EST - 2 months ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 13, 2026, 7:00 AM EST - 2 months ago

After A 55% Surge, Is JNJ Stock Still A Buy?

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 11, 2026, 2:23 PM EST - 2 months ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 9, 2026, 4:16 PM EST - 2 months ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 6, 2026, 7:00 PM EST - 2 months ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

The Big 3: JNJ, XOM, KO

Feb 5, 2026, 1:00 PM EST - 2 months ago

The Big 3: JNJ, XOM, KO

XOM KO

These hot S&P 500 stocks show where investors are heading as they run away from tech

Feb 4, 2026, 1:37 PM EST - 2 months ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 8:47 AM EST - 2 months ago

What's Behind The 50% Surge In JNJ Stock?

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 3, 2026, 3:00 AM EST - 2 months ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 2, 2026, 4:34 PM EST - 2 months ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 30, 2026, 7:19 AM EST - 2 months ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 6:32 PM EST - 2 months ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

parcha
parcha Apr. 11 at 1:31 AM
Cramer warns of ‘overconfident’ market after U.S.-Iran ceasefire $JNJ Tuesday brings earnings from Johnson & Johnson as well. Cramer loves this drugmaker because of its robust pipeline. This stock does have a habit of “getting hammered,” Cramer said, on the initial earnings results, then rallying once the conference call with management starts. “If it gets blasted, try to get some,” he added. In fact, the Charitable Trust started a position in Johnson & Johnson on Wednesday. https://www.cnbc.com/2026/04/10/cramer-warns-overconfident-market-after-us-iran-ceasefire.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 10 at 11:33 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile. We also covered these names. $COST $V $JNJ $JPM
0 · Reply
Skimman
Skimman Apr. 10 at 8:22 PM
$JNJ Grab some BEERS and do some reading .... have a GREAT WEEKEND.. LOL
0 · Reply
Skimman
Skimman Apr. 10 at 8:18 PM
$JNJ Earnings Tuesday.. Conference this Weekend with new Drugs in Washington Dc.. hope u did u research.. Conference starts today and ends Sunday.. hahahaha.. lets see who is laughing on Monday/ Tuesday.. lol
0 · Reply
Suite510
Suite510 Apr. 10 at 7:55 PM
$JNJ lol 😂 🥃🎁
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 10 at 6:33 PM
$JNJ $UNH defensive flows still active, but not panic-driven more like steady allocation into stable earnings
0 · Reply
trenddetector
trenddetector Apr. 10 at 5:30 PM
$JNJ There are now Care Pathways and Diagnostic Paths mapped out for Prostate, Breast, Colorectal, Lung, Pancreatic, Lymphoma, Leukemia, Melanoma, Bladder, Ovarian, Kidney, Thyroid, Brain Liver and Uterine/Endometrial Cancer with more coming. www.yourcancerpath.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 10 at 4:36 PM
🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-04-17 | Strike: $240.00 | Type: PUT Option Plan (premium): Entry: $4.68 Stop: $3.37 TP1: $6.08 TP2: $7.95 TP3: $11.22 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
NellyBush
NellyBush Apr. 10 at 12:43 PM
$JNJ $PTGX Bofa inaugural Doctor day KOL expects JNJ’s recently launched Icotyde (Ico; oral IL-23) to be the best oral option available in psoriasis and believes everyone on Otezla/Sotyktu (in theory) should get switched to Ico (all else equal), thus expects a fair amount of usage.
0 · Reply
Laurenoni
Laurenoni Apr. 10 at 11:30 AM
$JNJ above the open, strong demand
0 · Reply
DragonAlgo
DragonAlgo Apr. 10 at 12:22 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $4.30 Stop: $3.10 TP1: $5.59 TP2: $7.31 TP3: $10.32 🔗 https://dragonalgo.com
0 · Reply
snowPOW
snowPOW Apr. 9 at 9:03 PM
$BB Good to find out Johnson & Johnson $JNJ using QNX from BlackBerry in their heart equipment on the blowout beat earnings call this morning. QNX is expanding in medical equipment IoT for good reasons. $SIEMENS.NSE Yeah! THAT BlackBerry.
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 9 at 7:10 PM
$JNJ $UNH not loud, just consistently supported… that’s real demand
0 · Reply
Pearl_Power
Pearl_Power Apr. 9 at 6:13 PM
$JNJ setting up into earnings
0 · Reply
RyaKelly
RyaKelly Apr. 9 at 5:41 PM
$JNJ quiet strength is still strength
0 · Reply
trenddetector
trenddetector Apr. 9 at 5:15 PM
$JNJ Your Cancer Path url and beta is now live! www.yourcancerpath.com
0 · Reply
Wallst45
Wallst45 Apr. 9 at 3:27 PM
$JNJ $MDGL good choice
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 9 at 2:46 PM
Market Watch - Key Moves Today 👉Click to view @NasdaqPulse for timely updates amid the volatility. $AAPL showing some serious weakness today, down -0.58% and -0.63%. Looks like selling pressure is building. On the flip side, $JNJ is holding strong with a +0.42% gain. This one's showing resilience despite the broader market mood. The macro context is heavy right now — delays in big tech projects and broader sentiment issues are dragging things down. It's clear investors are cautious, especially in the tech space. Keep an eye on $AAPL for further signs of weakness, while $JNJ might continue to outperform in the current environment.
0 · Reply
1986iamwallstreet
1986iamwallstreet Apr. 9 at 2:34 PM
$JNJ go ahead and make the purchase of $MDGL for 20 billion
0 · Reply
NetworkNewsWire
NetworkNewsWire Apr. 9 at 1:13 PM
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value $NGTF $NVDA $JNJ $AMZN $TSLA https://ibn.fm/16tH7
0 · Reply
sblack9k
sblack9k Apr. 9 at 12:13 PM
$BB $JNJ
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 9 at 12:12 PM
$JNJ not exciting, just reliable - and that’s enough
0 · Reply